Recently approved Alzheimer drug raises questions that might never be answered


21 July 2021 - The FDA’s approval June 7 of the drug aducanumab was notable for a number of reasons.

It was the first time the FDA had approved an Alzheimer disease medication in 18 years, and the first time ever that the agency had approved a drug designed to target the underlying disease process.

Read JAMA Medical News & Perspectives

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Regulation